Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3033MR)

This product GTTS-WQ3033MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3033MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15442MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ1565MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ15212MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ13513MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ8970MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ10024MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ1016MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW